Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Crystagen
Also known as: Glu-Asp-Pro, EDP
Crystagen is a synthetic tripeptide (Glu-Asp-Pro) developed as an immune system bioregulator in the Khavinson research program. It is marketed to support overall immune function and normalize immune cell activity. Evidence is limited to in vitro studies and small Russian observational reports, with no controlled clinical trials available.
Risk Level
Low RiskDifficulty
Intermediate| Molecular Formula | C14H21N3O7 |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Proposed to regulate gene expression in immunocompetent cells, promoting balanced immune function. In vitro studies suggest modulation of lymphocyte proliferation and cytokine production. Theorized to enhance innate and adaptive immune responses through epigenetic mechanisms.
Dosing Research
Oral capsules: 10 mg 1-2 times daily for 15-30 days. Often combined with other immune bioregulators like Vilon or Thymosin Alpha-1 in comprehensive protocols. Repeat courses every 3-6 months.
Side Effects & Risks
No adverse effects documented in available literature. Considered low-risk due to the rapid degradation of short peptides. No controlled safety assessments have been performed. Immune modulation carries theoretical risks of autoimmune activation.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.